

Leptin/adiponectin ratio in overweight patients - gender differences

Selthofer-Relatić, Kristina; Radić, R.; Stupin, A.; Šišljagić, V.; Bošnjak, I.; Bulj, Nikola; Selthofer, R.; Delić Brkljačić, Diana

Source / Izvornik: **Diabetes & Vascular Disease Research**, 2018, 15, 260 - 262

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/doi:10.1177/1479164117752491>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:537715>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-05-20**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine
Digital Repository](#)





Središnja medicinska knjižnica

Selthofer-Relatić K., Radić R., Stupin A., Šišljagić V., Bošnjak I., Bulj N., Selthofer R., Delić Brkljačić D. (2018) *Leptin/adiponectin ratio in overweight patients – gender differences*. Diabetes & Vascular Disease Research, 15 (3). pp. 260-262. ISSN 1479-1641

<https://journals.sagepub.com/home/dvr>

<http://dx.doi.org/10.1177/1479164117752491>

<http://medlib.mef.hr/3399>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

Leptin/Adiponectin ratio in overweight patients – gender differences

Short report

Leptin/Adiponectin ratio – gender difference

^{1,2}Selthofer-Relatić K, ³Radić R, ⁴Stupin A, ⁵Šišljagić V, ¹Bošnjak I, ⁶Bulj N, ³Selthofer R, ⁶Delić Brkljačić D.

¹Department of Cardiovascular diseases, Osijek University Hospital, Osijek, Croatia

²Department for Internal Medicine, Faculty of Medicine, University of Osijek, Osijek, Croatia

³Department for Anatomy, Faculty of Medicine, University of Osijek, Osijek, Croatia

⁴Department for Physiology and Immunology, Faculty of Osijek, University of Osijek, Croatia

⁵Department for Surgery, Osijek University Hospital, Osijek, Croatia

⁶Department for Internal Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia

Abstract

OBJECTIVE: Obesity related atherosclerosis is a systemic disease with a background connected to multiple metabolic-neurohumoral pathways. The leptin/adiponectin ratio (L/A ratio) has been suggested as an atherosclerotic marker in obese patients. The aim of the study was to assess: a) the significance of the L/A ratio in overweight subjects; b) the relation with anthropometric/metabolic parameters; c) gender difference.

METHOD: The study included 80 adult male and female, overweight, non-diabetic patients. Biochemical blood analysis, anthropometric and cardiovascular measurements were performed. Serum leptin levels were measured with a RIA test and total adiponectin levels with ELISA. L/A ratios were calculated as ratios between total serum concentrations of leptin and adiponectin.

RESULTS: Differences between leptin, adiponectin serum levels and L/A ratios are presented in overweight persons, where females have a significantly higher L/A ratio than men ($p < 0.001$). In men, the L/A ratio showed a positive correlation with total cholesterol levels ($p = 0.011$), LDL ($p = 0.013$) and triglycerides ($p = 0.032$). In females, the L/A ratio correlated with anthropometric parameters of visceral obesity: waist circumference ($p = 0.001$) and waist-to-hip ratio ($p = 0.025$).

CONCLUSION: The L/A ratio could represent an atherosclerotic risk marker of the early stage of obesity. Gender plays a significant role in pathophysiological changes, with different clinical manifestations, where sex hormones have a crucial effect on neurohumoral adipose tissue activity.

Key words: adiponectin, gender, leptin, leptin/adiponectin ratio, overweight

Introduction:

Obesity related atherosclerosis is caused by multiple metabolic changes that result in acute and chronic cardio-cerebro-vascular diseases, whereby inflammation and endothelial dysfunction play a key role (1-3). The metabolic profile is associated with the presence of dyslipidemia, diabetes mellitus and hypertension, along with neurohumoral mechanisms caused by adipokines disbalance and cytokines activation. These factors, both individually and combined, have a great proatherogenic potential and each patient's atherosclerotic risk profile is unique (1).

Adult obesity is characterised by adipocyte hypertrophy. More leptin and less adiponectin is secreted, whereby leptin could accelerate and adiponectin restrain the development of atherosclerosis (4) acting directly on vascular cells (5), which makes them important mediators linking adiposity and atherosclerosis in the adipo-vascular axis (5). Both leptin and adiponectin could be individually associated with the development of atherosclerosis via plaque formation and progression and plaque rupture and thrombosis (2,3), and their combination might result in more atherosclerotic manifestations than their individual activity (6). The L/A ratio is a new surrogate marker for atherosclerosis in subjects with obesity and type 2 diabetes mellitus (4,6). It is a better parameter in monitoring for metabolic disorders (7) such as: a) atherosclerotic index in patients with diabetes type 2 regardless of body weight and obesity level (4,7); b) parameter for insulin resistance (7); c) screening for vascular risk and endothelial dysfunction (8,9).

From the clinical point of view, obesity related atherosclerosis is characterized by: insulin resistance, higher visceral fat, dyslipidemia, where a high L/A ratio and higher triglyceride serum levels may be additional obesity risk factors regardless of waist circumference and body mass index (10). Considering the relation between L/A ratio and an index of atherosclerosis in obese subjects with diabetes, the aim of this study was to examine the value of L/A ratio in overweight patients without diabetes, along with the other components of the metabolic syndrome, and to determine whether there are gender-based differences.

Materials and methods

The study included 80 adult, hypertensive, overweight subjects (BMI 25-29.99kg/m²), who were hospitalized at the Department for Cardiovascular Disease, University Hospital Osijek because of myocardial infarction. All involved subjects voluntarily agreed to

participate in the study and gave their written consent. The study was authorized by the hospital Ethics Committee.

Inclusion criteria for this study were: adult overweight subjects of both sexes, no diabetes mellitus, normal renal function. Included females were postmenopausal and were not taking hormonal replacement therapy. Other presented conventional risk factors were hypertension, dyslipidemia and smoking. Exclusion criteria for the study were: glucose intolerance and diabetes, renal failure, BMI above 30 kg/m² or less than 25 kg/m², systolic dysfunction (EF LV<55%), history of previous myocardial infarctions and/or acute stroke.

Medical history, physical examination, biochemical and anthropometric measurements, monitored values of blood pressure, transthoracic echocardiography and coronary angiography by a standard procedure were performed in all patients.

Leptin and adiponectin blood samples were taken from all subjects in the morning, at the same time. Serum leptin levels were measured using the RIA-CT method and total circulating adiponectin serum levels were measured using ELISA for quantitative determination of human adiponectin, Biosource Europe S.A, Belgium. L/A ratio was calculated as the ratio between total serum concentrations of leptin and adiponectin.

Statistical analysis

All statistical tests were two-sided and carried out to a significance level (P) of 0.05. Distribution normality for leptin/adiponectin level was tested using Shapiro-Wilks test. According to results of the Shapiro-Wilks test, the nonparametric Mann-Whitney test was used. To verify relationship between univariate relations, we used the Spearman method. Data was prepared for analysis in Microsoft Excel 2003. Statistical analysis was done by SPSS 15.0 for Windows Evaluation Version and Statistica 7.1.

Results

Subjects in both groups were Caucasian, overweight, with conventional risk factors, normal renal function and no other significant co-morbidities. The average age in the group of male subjects was 59.47±7.60 years while it was 64.10±7.59 years in female subjects.

According to the results, leptin and adiponectin levels varied in males and females (11,12). Leptin levels were statistically significantly higher in females compared to the male group (p<0.001); also total adiponectin levels were higher in the female group than in the male group (p=0.006). According to these results, the L/A ratio showed a gender-related difference, where the L/A ratio is lower in men than in women p<0.001 (Figure1).

Statistically significant correlation was found between the L/A ratio and metabolic parameters in male subjects (total cholesterol $p=0.011$, triglycerides $p=0.032$, LDL $p=0.013$), but there was no significant correlation with glucose level in this sample size. The results suggest that correlation might be positive in a study with a larger sample. In females, the L/A ratio significantly correlated with anthropometric parameters (waist circumference $p=0.001$, waist-to-hip ratio $p=0.025$). In both groups of patients, the L/A ratio did not correlate with weight in both genders (male $p=0.380$, female $p=0.350$) or with BMI (male $p=0.091$, female $p=0.080$).

Discussion

Visceral type of obesity is an independent risk factor for atherosclerosis, but the personal profile is unique as a result of the complexity of included metabolic, genetic and environmental risk factors and influences. Neurohumoral mechanisms that link atherosclerosis with obesity are: adipocytokines production, endothelial dysfunction and chronic inflammation. Regarding opposite effect of leptin and adiponectin on vascular endothelium, angiogenesis, inflammatory and thrombogenic state in obesity, it is logical to consider the L/A ratio as a possible marker for atherosclerosis.

There are still unanswered questions: can the L/A ratio serve as an early atherosclerotic marker in the pre-stage of obesity or in patients without diabetes mellitus? What is the clinical relevance of the L/A ratio and is there a gender-related difference? Data in this area are very scarce, especially if one takes into account differences based on race and ethnicity.

Results from our study confirm the significance of gender differences of the L/A ratio and its correlation with anthropometric and metabolic profiles. The L/A ratio is not related with BMI or weight measurements, but in females it is related with visceral type of obesity, while this is not evident in males in this early stage of obesity. This is probably caused by hormone-related differences in body structure and distribution of adipose tissue in men and women, especially in overweight persons since it is not clear if significant changes in synthetic activity of adipose tissue start at this obesity level (4). It is possible that visceral obesity is manifested earlier in women than in men at lower levels of obesity. Also, in early stages of obesity, adipose tissue is less active as a possible consequence of low-grade adipokines inflammation (7,8).

On the other hand, the L/A ratio correlates with lipidogram components in men, while there is no correlation in women at this level of obesity. The reason for this might be a still unexplained activity of fat cells, as well as volume of visceral tissue. There is positive

correlation between L/A ratio and glycaemia at low levels of obesity, when glucose levels in blood are still normal, both in men and in women, which might indicate that there is significant correlation between the L/A ratio and hyperglycaemia and other disorders of glucose metabolism.

Conclusion

Gender-related differences of the L/A ratio suggest that sex hormones might influence body adipose tissue composition and affect certain metabolic parameters. This could be a result of sex hormone-induced changes of the mechanisms of adipokine synthesis and consequent changes of adipokine activity as signaling factors. Overweight is a warning sign in cardiovascular risk assessment as well as a risk factor for development of atherosclerosis. Since obesity has ceased to be only a lifestyle consequence and has become a serious disease, early detection of risk factors for its development, recognizing the disease in its early stages, developing strategies for its prevention and treatment, have become a necessity. Further research in this area is needed, especially of the influence of sex hormones on obesity development and influence on metabolic changes.

Acknowledgements: None.

Funding: This research received no grant from any funding agency in the public, commercial or not-for-profit sectors.

Disclosures: The authors declare that there is no conflict of interest.

References:

1. van Rooy MJ, Pretorius E. Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischaemic events. *Curr Med Chem* 2014;21(19):2121-2129.
2. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? *Am J Physiol Heart Circ Physiol* 2007;292:H1655-H1663.
3. Schutte AE, Schutte R. Leptina: a cardiovascular perspective. *JEMDSA* 2012;17(2):72-76.
4. Kotani K, Sakane N, Saiga K, Kurozawa Y. Leptin:adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness. *Diabetologia* 2005;48:2684-2686.
5. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. *J Biol Chem* 2002;277:37487-37491.
6. Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada, Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada K, Kuzuya H, Shimatsu A, Ogawa Y. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. *Diabetes Care* 2004;27:2488-2490.
7. Norata GD, Rasseli S, Grigore L, Garlascehelli K, Dozio E, Magni P, Catapano AL. Leptin:Adiponectin Ratio is independent predictor of intima media thickness of the common carotid artery. *Stroke* 2007;28:2844-2846.
8. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, Flyvbjerg A, Walker M, Højlund K, Nolan JJ; European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group), Savage DB. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. *Diabetologia* 2009;52:2345-2349.
9. Kieć-Klimczak M, Malczewska-Malec M, Huszno B. Leptin to adiponectin ratio, as an index of insulin resistance and atherosclerosis development. *Przegl Lek* 2008;65(12):844-849.
10. Labruna G, Pasanisi F, Nardelli C, Caso R, Vitale DF, Contaldo F, Sacchetti L. High leptin/adiponectin ratio and serum triglycerides are associated with „at-risk“ phenotype in young severely obese patients. *Obesity (Silver Spring)* 2011;19(7):1492-14.
11. Selthofer-Relatić K, Radić R, Vizjak V, Včev A, Kosović P, Bošnjak I, Selthofer R. “Hyperleptinemia- non-haemodynamic risk factor for the left ventricular hypertrophy development in hypertensive overweight females”. *Coll Antropoll* 2008;32(3):681-685.

12. Selthofer-Relatić K, Radić R, Včev A, Steiner R, Vizjak V, Šram M, Tripolski M, Kosović P, Bošnjak I, Selthofer R. Low adiponectin serum level – reduced protective effect on the left ventricular wall thickness. Coll Antropol 2011;35(3):787-791.




Figure1. L/A ratio and gender difference in overweight